Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 88Neoplasms 11Neoplasm Metastasis 10Glioma 8Ovarian Neoplasms 6Melanoma 6Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Liposarcoma 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Recurrence 4Medulloblastoma 4Endometrial Neoplasms 4Diffuse Intrinsic Pontine Glioma 4Colorectal Neoplasms 4Brain Neoplasms 4Neuroblastoma 3Neoplasms by Site 3Lymphoma 3Hereditary Sensory and Autonomic Neuropathies 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Astrocytoma 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Multiple Endocrine Neoplasia Type 1 2

Interventions

Imatinib Mesylate 67Sunitinib 27nilotinib 14regorafenib 13ripretinib 10avapritinib 5Ipilimumab 5Dasatinib 5spartalizumab 4Laparoscopy 4CTLA-4 Antigen 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Bevacizumab 3trametinib 2tanespimycin 2ponatinib 2pembrolizumab 2masitinib 2famitinib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Stromal Tumors × ribociclib × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡